The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease

Brain

Volumn 127, Issue 2, 2004, Pages 420-430

  Bandopadhyay, Rina ^a   Kingsbury, Ann E ^a   Cookson, Mark R ^d   Reid, Andrew R ^a   Evans, Ian M ^c   Hope, Andrew D ^a   Pittman, Alan M ^a   Lashley, Tammaryn ^b   Canet Aviles, Rosa ^d   Miller, David W ^d   McLendon, Chris ^d   Strand, Catherine ^b   Leonard, Andrew J ^c   Abou Sleiman, Patrick M ^b   Healy, Daniel G ^b   Ariga, Hiroyashi ^e,f   Wood, Nicholas W ^b   De Silva, Rohan ^a   Revesz, Tamas ^b   Hardy, John A ^d   Lees, Andrew J ^a   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e HOKKAIDO UNIVERSITY   (Japan)

^f JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

2D gel electrophoresis; DJ 1; Immunohistochemistry; Paraquat; Parkinson's disease

Indexed keywords

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DJ 1 GENE; FEMALE; FRONTAL CORTEX; GENE; GENE EXPRESSION; GENE MUTATION; GLIA CELL; HUMAN; HUMAN CELL; IMMUNOELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; MALE; NERVE CELL CULTURE; NEUROLOGIC DISEASE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SUBSTANTIA NIGRA; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; ASTROCYTES; BLOTTING, WESTERN; BRAIN; CELLS, CULTURED; FEMALE; FRONTAL LOBE; HIPPOCAMPUS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEWY BODIES; MALE; MICE; NEURONS; ONCOGENE PROTEINS; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN ISOFORMS; SUBSTANTIA NIGRA;

EID: 10744224738     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awh054     Document Type: Article

References (56)

1. Abbas N, Lucking CB, Ricard S, Durr A, Bonifati V, De Michele G, et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum Mol Genet 1999; 8: 567-74.
2. Abou-Sleiman PM, Healy DG, Quinn NP, Lees AJ, Wood NW. The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann Neurol 2003; 54: 283-6.
3. Allen S, Heath PR, Kirby J, Wharton SB, Cookson MR, Menzies FM, et al. Analysis of the cytosolic proteome in a cell culture model of familial amyotrophic lateral sclerosis reveals alterations to the proteasome, antioxidant defenses, and nitric oxide synthetic pathways. J Biol Chem 2003; 278: 6371-83.
4. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256-9.
5. Chung KK, Dawson VL, Dawson TM. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci 2001; 24 (11 Suppl): S7-14.
6. Cookson MR. Pathways to parkinsonism. Neuron 2003; 37: 7-10.
7. Czlonkowska A, Kurkowska-Jastrzebska I, Czlonkowski A, Peter D, Stefano GB. Immune processes in the pathogenesis of Parkinson's disease-a potential role for microglia and nitric oxide. Med Sci Monit 2002; 8: RA 165-77.
8. Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 1993; 52: 1-6.
9. Dawson TM, Dawson VL. Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J Clin Invest 2003; 111: 145-51.
10. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62: 10-5.
11. Demasi M, Davies KJ. Proteasome inhibitors induce intracellular protein aggregation and cell death by an oxygen-dependent mechanism. FEBS Lett 2003; 542: 89-94.
12. Ding Q, Keller JN. Proteasome inhibition in oxidative stress neurotoxicity: implications for heat shock proteins. J Neurochem 2001; 77: 1010-7.
13. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature 2000; 404: 394-8.
14. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996; 55: 259-72.
15. Forno LS, DeLanney LE, Irwin I, Di Monte D, Langston JW. Astrocytes and Parkinson's disease. Prog Brain Res 1992; 94: 429-36.
16. Grune T, Merker K, Sandig G, Davies KJ. Selective degradation of oxidatively modified protein substrates by the proteasome. Biochem Biophys Res Commun 2003; 305: 709-18.
17. Hague S, Rogaeva E, Hernandez D, Gulick C, Singleton A, Hanson M, et al. Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol 2003; 54: 271-4.
18. Hardy J, Cookson MR, Singleton A. genes and parkinsonism. Lancet Neurol 2003; 2: 221-8.
19. Hayashi S, Wakabayashi K, Ishikawa A, Nagai H, Saito M, Maruyama M, et al. An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov Disord 2000; 15: 884-8.
20. Hishikawa N, Hashizume Y, Yoshida M, Sobue G. Widespread occurrence of argyrophilic glial inclusions in Parkinson's disease. Neuropathol Appl Neurobiol 2001; 27: 362-72.
21. Hod Y, Pentyala SN, Whyard TC, El-Maghrabi MR. Identification and characterization of a novel protein that regulates RNA-protein interaction. J Cell Biochem 1999; 72: 435-44.
22. Honbou K, Suzuki NN, Horiuchi M, Niki T, Taira T, Ariga H, et al. The crystal structure of DJ-1, a protein related to male fertility and Parkinson's disease. J Biol Chem 2003; 278: 31380-4.
23. Hou JG, Cohen G, Mytilineou C. Basic fibroblast growth factor stimulation of glial cells protects dopamine neurons from 6-hydroxydopamine toxicity: involvement of the glutathione system. J Neurochem 1997; 69: 76-83.
24. Ishikawa A, Takahashi H. Clinical and neuropathological aspects of autosomal recessive juvenile parkinsonism. J Neurol 1998; 245 (11 Suppl 3): P4-9.
25. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003; 53 Suppl 3: S26-36; discussion S36-8.
26. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-8.
27. Ledesma MD, Galvan C, Hellias B, Dotti C, Jensen PH. Astrocytic but not neuronal increased expression and redistribution of parkin during unfolded protein stress. J Neurochem 2002; 83: 1431-40.
28. Lee SJ, Kim SJ, Kim IK, Ko J, Jeong CS, Kim GH, et al. Crystal structures of human DJ-1 and Escherichia coli Hsp 31 which share an evolutionarily conserved domain. J Biol Chem 2003; 45: 44552-9.
29. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998; 395: 451-2.
30. Lowe J, McDermott H, Landon M, Mayer RJ, Wilkinson KD. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J Pathol 1990; 161: 153-60.
31. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, et al. Dopaminergic loss and inclusion body formation in alphasynuclein mice: implications for neurodegenerative disorders. Science 2000; 287: 1265-9.
32. McNaught KS, Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett 2001; 297: 191-4.
33. Mena MA, de Bernardo S, Casarejos MJ, Canals S, Rodriguez-Martin E. The role of astroglia on the survival of dopamine neurons. Mol Neurobiol 2002; 25: 245-63.
34. Miller DW, Ahmad R, Hague S, Baptista M, Canet-Aviles R, McLendon C, et al. L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome pathway. J Biol Chem 2003; 278: 36588-95.
35. Mirza B, Hadberg H, Thomsen P, Moos T. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 2000; 95: 425-32.
36. Mitsumoto A, Nakagawa Y. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radic Res 2001; 35: 885-93.
37. Mitsumoto A, Nakagawa Y, Takeuchi A, Okawa K, Iwamatsu A, Takanezawa Y. Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat. Free Radic Res 2001; 35: 301-10.
38. Mori H, Kondo T, Yokochi M, Matsumine H, Nakagawa-Hattori Y, Miyake T, et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 1998; 51: 890-2.
39. Nagakubo D, Taira T, Kitaura H, Ikeda M, Tamai K, Iguchi-Ariga SM, et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun 1997; 231: 509-13.
40. Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm 1997; 104: 661-77.
41. Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002; 36: 1007-19.
42. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-7.
43. Schlossmacher MG, Frosch MP, Gai WP, Medina M, Sharma N, Forno L, et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol 2002; 160: 1655-67.
44. Shimura H, Hattori N, Kubo S, Yoshikawa M, Kitada T, Matsumine H, et al. Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol 1999; 45: 668-72.
45. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genet 2000; 25: 302-5.
46. Shringarpure R, Grune T, Mehlhase J, Davies KJ. Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J Biol Chem 2003; 278: 311-8.
47. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994; 36: 348-55.
48. Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992; 142: 128-30.
49. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-40.
50. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA 1998; 95: 6469-73.
51. Takahashi K, Taira T, Niki T, Seino C, Iguchi-Ariga SM, Ariga H. DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor. J Biol Chem 2001; 276: 37556-63.
52. Tao X, Tong L. Crystal structure of human DJ-1, a protein associated with early-onset Parkinson's disease. J Biol Chem 2003; 278: 31372-9.
53. Teismann P, Tieu K, Cohen O, Choi DK, Wu du C, Marks D, et al. Pathogenic role of glial cells in Parkinson's disease. Mov Disord 2003; 18: 121-9.
54. Tieu K, Ashe PC, Zuo DM, Yu PH. Inhibition of 6-hydroxydopamine-induced p53 expression and survival of neuroblastoma cells following interaction with astrocytes. Neuroscience 2001; 103: 125-32.
55. Wagenfeld A, Gromoll J, Cooper TG. Molecular cloning and expression of rat contraception associated protein 1 (CAP1), a protein putatively involved in fertilization. Biochem Biophys Res Commun 1998; 251: 545-9.
56. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol 1969; 21: 343-54.